Cyclophosphamide Treatment for Metastatic Soft Tissue Sarcoma

Publisher Website
Google Scholar
Abstract
INTEREST in the use of chemotherapeutic agents for palliating the clinical effects of malignant neoplasms is increasing. Cancer chemotherapy is especially useful when recurrence or metastasis follows surgery, or radiotherapy, or both and when massive size or the presence of distant metastases at the time of discovery precludes the use of these conventional methods. Most childhood cancers have some degree of responsiveness to one or more of the various available chemical compounds. Sarcomas of the soft tissues in children tend to be highly malignant and to have a rather discouraging outlook. Bowden's1five-year survival rate for 602 patients with soft-part sarcomas was 37%. Other mortality figures are higher. Lawrence et al2reported 9 of 48 patients with embryonal rhabdomyosarcoma surviving and Masson and Soule3found that 88% of traced patients with embryonal rhabdomyosarcoma of the head and neck died within five years. A number of agents have